The interaction between obstructive sleep apnea and long sleep duration was associated with a nearly 3-fold chance of having a coronary artery calcium score of >100.
Obstructive sleep apnea increases the risk for chronic kidney disease in patients who have recovered from an episode of acute cardiogenic pulmonary edema.
A simple, efficient algorithm has been developed that will help to classify symptom subtypes among patients with obstructive sleep apnea based on only 6 symptom items.
Researchers find treatment with pitolisant is associated with reductions in excessive daytime sleepiness and cataplexy over a 1-year period in patients with narcolepsy.
Cognitive behavioral therapy (CBT) may reduce the incidence of insomnia symptoms in adolescents, according to study data presented at the 2019 World Sleep Congress.
Researchers sought to explore the clinical presentations of sleep-disordered breathing in patients with suspected ROHHAD.
Short average sleep duration and short weekend catch-up sleep duration is associated with increased risk for obesity.
Investigators sought to determine the mental health needs of evacuees of devastating wildfires in Canada and to distribute evidence-based tools to promote resilience.
Researchers examined the association between orexin-A levels in CSF and traits of nocturnal sleep fragmentation, as evaluated by polysomnography, in a large cohort of adults and children with self-reported hypersomnolence.
Researchers find once-daily treatment with lemborexant is associated with a noticeable reduction in subject-reported fatigue over 6 month period in patients with insomnia disorder.
Researchers discovered that bariatric surgery led to a significant decrease in BMI, waist circumference, neck circumference, and AHI compared with in the optimized clinical treatment group.
Meal consumption in the evening is greater in obese adolescents compared with overweight or normal weight subjects, with later circadian phase of peak intake and lower amplitude.
Late chronotype and daytime sleepiness are associated with unhealthy life habits, including consumption of alcohol and caffeinated beverages and smoking high school students.
Treatment with pitolisant, a potent and highly selective H3-receptor antagonist/inverse agonist, reduces excessive daytime sleepiness and cataplexy in patients with narcolepsy.
Common early onset treatment-emergent adverse events associated with solriamfetol include headache, anorexia, and nausea in patients with obstructive sleep apnea and narcolepsy.